1. Volume 123, Issue 1, Pages 106-111 (July 2002)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease 
Severine Vermeire, Edouard Louis, Paul Rutgeerts, Martine De Vos, Andre Van Gossum, Jacques Belaiche, Paul Pescatore, Rene Fiasse, Paul Pelckmans, Robert Vlietinck, Françoise Merlin, Habib Zouali, Gilles Thomas, Jean–Frederic Colombel, Jean–Pierre Hugot 
Gastroenterology 
Volume 123, Issue 1, Pages (July 2002)
DOI: /gast
Copyright © 2002 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Percentage of patients carrying 0, 1, or 2 doses of NOD2/CARD15 mutations according to their infliximab responder status.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

3. Fig. 2
TNF production (pg/mL · mg) according to the NOD2/CARD15 genotypes: wild-type (WT) and NOD2/CARD15 mutation carriers (variant) in uninflamed and inflamed colonic biopsy specimens. Decreased TNF production was observed in mutation carriers, but significance was not reached.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions